Phase II trial of raltitrexed ('Tomudex') in advanced small-cell lung cancer.

Raltitrexed, a thymidylate synthase inhibitor, was given to 21 patients with advanced small-cell lung cancer, at a dose of 3 mg m(-2) as a 15-min intravenous infusion at 21-day intervals. All of the patients had extensive disease and 17 had received prior therapy. Patients with disease refractory to...

Descripción completa

Detalles Bibliográficos
Autores principales: Woll, P. J., Basser, R., Le Chevalier, T., Drings, P., Perez Manga, G., Adenis, A., Seymour, L., Smith, F., Thatcher, N.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1997
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2223947/
https://www.ncbi.nlm.nih.gov/pubmed/9231930

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2223947/
https://www.ncbi.nlm.nih.gov/pubmed/9231930

Ejemplares similares